ATNM insider trading
NYSE American HealthcareActinium Pharmaceuticals, Inc.: insider trade history from SEC Form 4 filings.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Company website: www.actiniumpharma.com
ATNM insider activity at a glance
FilingIQ tracks 173 insider transactions for ATNM in filings since Mar 16, 2015. The most recent transaction is dated Oct 14, 2026.
Across the full history, 26 open-market purchases
and 120 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest ATNM Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ATNM?
- FilingIQ tracks 173 Form 4 insider transactions for ATNM (Actinium Pharmaceuticals, Inc.), covering filings from Mar 16, 2015 onwards. 8 of those are dated within the last 90 days.
- Are ATNM insiders net buyers or net sellers?
- Across the full Form 4 history for ATNM, 26 transactions (15%) were open-market purchases and 120 (69%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ATNM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is ATNM in?
- Actinium Pharmaceuticals, Inc. (ATNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $32.55M.
Methodology & sources
Every ATNM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.